Christopher M. Murawsky

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests

Christopher M. Murawsky has a total of 135 co-authors. Here are the top co-authors by number of shared publications:

Angela Coxon
Amgen Inc. 3 Thousand Oaks, CA
25 shared publications
Binnaz K. Staley
Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
25 shared publications
Bram Estes
Torrey Mesa Research Institute, Syngenta Research and Technology, 3115 Merryfield Row, San Diego, CA 92121, USA
25 shared publications
Cong Li
Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
25 shared publications
Famke Aeffner
Amgen, Inc., South San Francisco, California, USA
25 shared publications
Fei Li
Department of Biochemistry and Biophysics, UCSF School of Medicine, San Francisco, USA
25 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
AMG 509 cross-reactivity to other species.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S5 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
AMG 509 cross-reactivity to other species.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Cryo-EM data collection, refinement, and validation statistics.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Cryo-EM data collection, refinement, and validation statistics.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
This file contains Methods for Supplementary Data.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Methods from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
This file contains Methods for Supplementary Data.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Antibodies used in this study.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Antibodies used in this study.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Antibodies used in this study.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Antibodies used in this study.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Avidity-dependent activity of AMG 509.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Avidity-dependent activity of AMG 509.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Binding properties of AMG 509 and monovalent anti-STEAP1 XmAb molecules.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
Binding properties of AMG 509 and monovalent anti-STEAP1 XmAb molecules.
Open Access
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
This file contains Methods for Supplementary Data.
Website
Google Scholar
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Methods from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, et al.
This file contains Methods for Supplementary Data.

Show all